Monoclonal antibodyFDA-approvedSecond-line
Blinatumomab
How it works
Binds to CD19 on cancer cells, blocking growth signals and flagging the cells for immune destruction.
Cancer types
Leukemia— Relapsed or refractory B-cell precursor ALL
Efficacy
In clinical trials, around 40% of ALL patients achieved a complete response, with a median progression-free survival of approximately 9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Blinatumomab for Infants with KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | Leukemia | phase-3 | — | Source → |
| Blinatumomab Consolidation in Real World: A Clinical Trial for B-Cell Acute Lymphoblastic Leukaemia | Leukemia | preclinical | — | Source → |
| Comparing Blinatumomab Alone to Blinatumomab with Nivolumab in B-Cell Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | Leukemia | phase-3 | — | Source → |
| Testing Blinatumomab for Leukemia and Lymphoma After Stem Cell Transplant | Leukemia | phase-1 | — | Source → |
| Understanding Resistance to Blinatumomab in Leukemia Treatment | Leukemia | review | — | Source → |
| Testing a Combination of Medications for Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Blinatumomab and Low-Intensity Chemotherapy for Older Leukemia Patients | Leukemia | phase-2 | — | Source → |
| Testing Blinatumomab and Chemotherapy for B Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Blinatumomab and Asciminib for Acute Lymphoblastic Leukemia | Leukemia | phase-1 | — | Source → |
| Testing New Treatments for Relapsed or Refractory Leukemia | Leukemia | phase-1 | — | Source → |
| New Treatment Options for Acute Lymphoblastic Leukemia | Leukemia | phase-3 | — | Source → |
| Combining blinatumomab and dasatinib for pediatric leukemia treatment | Leukemia | observational | At a median follow-up of 13 months, all patients were alive without disease relapse. | Source → |
| Reducing Neurotoxicity in Acute Lymphoblastic Leukemia Patients | Leukemia | phase-2 | — | Source → |
| Testing Blinatumomab and Tyrosine Kinase Inhibitor Therapy for Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Blinatumomab in Older Patients with Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Combination Therapy for CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Blinatumomab Helps Adult Leukemia Patients Achieve Remission | Leukemia | phase-2 | — | Source → |
| Blinatumomab Efficacy in Children with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Leukemia | observational | A 1-year overall survival rate of (92.3±7.4)% was observed. | Source → |
| Shortened Blinatumomab Treatment for Children with Leukemia | Leukemia | observational | The estimated 3-year overall survival (OS) was 54%, and the relapse-free survival (RFS) was 44%. Five patients (62%) achieved CR with undetectable MRD, and all four patients who initiated treatment because of persistent MRD achieved MRD clearance (100%). | Source → |
| Chemotherapy-Free Treatment for Leukemia in Jehovah's Witness Patient | Leukemia | observational | — | Source → |
| Blinatumomab Improves Outcomes for Infants with Rare Leukemia | Leukemia | phase-3 | A 4-year disease-free survival of 83.3% versus 44.0% and a 4-year overall survival of 93.3% versus 60.2% were observed. | Source → |
| Blinatumomab Affects Different Types of T-Cells Differently | Leukemia | lab-study | — | Source → |
| Blinatumomab Improves Survival for B-ALL Patients Before Transplant | Leukemia | phase-3 | The 18-month cumulative incidence of relapse was significantly lower (0.05) and chronic graft-versus-host disease (GVHD) was 14.8% compared to 41.8% in the control group. | Source → |
| Blinatumomab Efficacy and Safety in Adult B-Cell Leukemia Patients | Leukemia | observational | In the R/R B-ALL group, 11 patients achieved CR/CRh/CRi and 10 patients achieved complete MRD response. | Source → |
| Blinatumomab Improves Survival in Relapsed Leukemia Patients | Leukemia | phase-2 | 45.5% of patients achieved complete remission after 2 cycles of blinatumomab therapy. | Source → |
| Blinatumomab's Use in Pediatric B-ALL: A Review | Leukemia | review | — | Source → |
| Expert Recommendations for Blinatumomab in Pediatric B-ALL | Leukemia | review | — | Source → |
| Adding blinatumomab to leukemia treatment is safe and feasible for young adults | Leukemia | phase-2 | — | Source → |
| Blinatumomab's Role in Treating Adult Leukaemia | Leukemia | review | Blinatumomab induces a high rate of deep molecular response. | Source → |
| Immunotherapy Response Varies in B-ALL Patients | Leukemia | observational | — | Source → |
| Combination Therapy for Rare Leukemia Relapse | Leukemia | observational | — | Source → |
| Blinatumomab Shows Promise in Treating Adult Leukemia | Leukemia | observational | Of the 10 patients with relapsed/refractory B-ALL, 8 achieved complete remission (CR) and minimal residual disease (MRD) negativity after one blinatumomab treatment cycle. | Source → |
| Combining Immunotherapy with Chemotherapy for Adult B-Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Researchers Test Blinatumomab with Stem Cell Transplant for High-Risk Leukemia | Leukemia | observational | After a 2-year follow-up, 2/3 of patients remained disease-free. | Source → |
| Blinatumomab Effective in Pediatric B-ALL Patients | Leukemia | observational | The CR rate was 81.8% in R/R and 82.5% in CR-MRD patients. | Source → |
| Blinatumomab Efficacy in Pediatric B-Cell Leukemia | Leukemia | review | — | Source → |
| Blinatumomab Helps Clear Cancer Cells in Some Children with Leukemia | Leukemia | observational | 55.56% of patients successfully achieved undetectable levels of MRD after blinatumomab treatment. | Source → |
| Blinatumomab May Cause Neutropenia in B-ALL Patients | Leukemia | observational | — | Source → |
| Blinatumomab Shows Promise in Treating Richter Transformation | Leukemia | phase-2 | The overall response rate in the full-analysis-set was 46% (n = 18), with CR in 14 (36%) patients. | Source → |
| Combining Ponatinib and Blinatumomab in Leukemia Treatment | Leukemia | phase-2 | The complete molecular response rate was 83% and the rate of measurable residual disease negativity was 98%. | Source → |
| Rare Brain Condition Linked to Leukemia Treatment in Children | Leukemia | observational | — | Source → |
| New Treatment Options for Adult Leukemia Patients | Leukemia | phase-2 | — | Source → |
| New Treatment Approach for Adult Leukemia Shows Promise | Leukemia | phase-3 | Disease-free survival, overall survival, and event-free survival are 75.8%, 80.7%, and 74.6%, respectively. | Source → |
| Blinatumomab Helps Children with Leukemia and Fungal Infections | Leukemia | observational | — | Source → |
| New Treatment Option for Children with Leukemia | Leukemia | phase-3 | At a median follow-up of 22 months, the 2-year outcomes of the 80 matched Blin-CT group patients were similar to those of 192 controls (EFS, 95% [95% CI, 85 to 98] 90% [95% CI, 65 to 93] and OS, 97% [95% CI, 86 to 99] 94% [95% CI, 89 to 96]). | Source → |
| New Treatment Combination Shows Promise in Infant Leukemia | Leukemia | phase-3 | Two-year disease-free survival was 81.6% and overall survival was 93.3% in our study. | Source → |
| Combining Chemotherapy and Blinatumomab for Leukaemia Treatment | Leukemia | phase-2 | Estimated 3-year relapse-free survival was 73% (95% CI 56-85). | Source → |
| Lab Study Investigates Why Some Patients Don't Respond to Cancer Treatment | Leukemia | lab-study | — | Source → |
| Rare Brain Disease Linked to Leukemia Treatment | Leukemia | observational | — | Source → |
| Comparing Two Treatments for Relapsed Leukemia in Children | Leukemia | phase-3 | Treatment with tisagenlecleucel was associated with a statistically significant higher likelihood of achieving CR (odds ratios: 6.71-9.76) and a lower hazard of death (hazard ratios: 0.26-0.32) than treatment with blinatumomab. | Source → |
| Blinatumomab Improves Event-Free Survival in High-Risk B-Cell Leukemia | Leukemia | phase-3 | The incidence of events in the blinatumomab vs consolidation chemotherapy groups was 31% vs 57%. | Source → |
| T cell analysis sheds light on blinatumomab resistance in leukemia patients | Leukemia | lab-study | — | Source → |
| Nurse Practitioners Improve Blinatumomab Infusion Care | Leukemia | observational | — | Source → |
| Second-line treatment for adult leukemia patients shows promise | Leukemia | observational | The 3-year overall survival rate was 31%, and it was 57% with third-generation TKI combinations. | Source → |
| Expert Consensus on Acute Lymphoblastic Leukemia Treatment | Leukemia | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.